Vertex Pharmaceuticals Inc annual operating income for fiscal TTM was $4.8 billion, an increase of 0.3% from $4.8 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | $4.8B | $4.8B | ($233M) | $3.8B | $4.3B | $2.8B | $2.9B | $1.2B | $635M | $123M | $10M | ($469M) | ($692M) | ($903M) | $2M | $114M | ($696M) | ($613M) | ($463M) | ($420M) | ($229M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | $1.1B | $1.3B | $1.2B | $1.2B | $630M | $1.0B | $1.1B | ($3.5B) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More VRTX metrics: Revenue · Gross Profit · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All VRTX financial statements → Interactive VRTX charts →
About TickerBase · Data methodology & sources